- ‘There is always a first’: Why US biotech Axiom will begin its IPO journey in Hong KongAxiom Biosciences intends to pursue an IPO on the Hong Kong Stock Exchange (HKEX), followed by a co-listing on the Nasdaq—a strategy the company claims is the first U.S. biotech to use.Fierce Biotech · 6d ago↗ source
- STAT+: The next step of site-neutral, and a fiery PBM hearingMedicare proposes to reduce payments to hospitals for certain drugs and imaging services.STAT · 6d ago↗ source
- FDA’s radical transparency policy for rejections runs into legal uncertaintyHaving started to publish CRLs without consulting the public, the FDA is under pressure to change course amid concerns it failed to openly and fully evaluate a complex issue.BioSpace · 6d ago